0000000000634114

AUTHOR

Michele Simbolo

showing 4 related works from this author

Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas

2022

Undifferentiated sarcomatoid carcinoma (USC) of the pancreas is a rare but especially aggressive variant of pancreatic ductal adenocarcinoma (PDAC), composed of at least 80% of sarcomatoid cells. This study aimed to elucidate its clinicopathological and molecular features. The study cohort included 10 patients with pancreatic USC. Clinicopathological parameters were determined for each patient. The molecular profile was investigated using next-generation sequencing (NGS). Histologically, all tumors were hypercellular neoplasms with spindle-shaped or sarcomatoid cells. All patients showed vascular and perineural invasion. Most patients had a poor prognosis. NGS showed important similarities …

GenomicsPancreatic cancerAdenocarcinomaKRAS; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Sarcomatoid; UndifferentiatedSarcomatoidPathology and Forensic MedicineKRAS Pancreatic cancer Pancreatic ductal adenocarcinoma Sarcomatoid UndifferentiatedPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)Pancreatic ductal adenocarcinomaMutationUndifferentiatedKRASHumansMyeloid Cell Leukemia Sequence 1 ProteinPancreasCarcinoma Pancreatic Ductal
researchProduct

PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer

2017

AbstractCombined MAPK/PI3K pathway inhibition represents an attractive, albeit toxic, therapeutic strategy in oncology. Since PTEN lies at the intersection of these two pathways, we investigated whether PTEN status determines the functional response to combined pathway inhibition. PTEN (gene, mRNA, and protein) status was extensively characterized in a panel of cancer cell lines and combined MEK/mTOR inhibition displayed highly synergistic pharmacologic interactions almost exclusively in PTEN-loss models. Genetic manipulation of PTEN status confirmed a mechanistic role for PTEN in determining the functional outcome of combined pathway blockade. Proteomic analysis showed greater phosphoprote…

0301 basic medicineMAPK/ERK pathwayPTENRNA interferenceprotein Kinase inhibitorsRNA Small InterferinghumansPhosphoinositide-3 Kinase InhibitorsAnimals; cell line tumor; drug synergism; everolimus; female; humans; Janus Kinase 1; MAP Kinase Kinase Kinases; mice; neoplastic stem cells; PTEN phosphohydrolase; phosphatidylinositol 3-Kinases; protein Kinase inhibitors; proto-oncogene Proteins c-akt; Pyridones; Pyrimidinones; RNA Interference; RNA Small Interfering; STAT3 Transcription Factor; TOR Serine-Threonine KinasesMultidisciplinaryMAPK/PI3K pathway inhibitiononcology MAPK/PI3K pathway inhibitionTOR Serine-Threonine Kinasescell lineMAPK/PI3K inhibition oncology. inhibition. PTEN gene mRNA cancer cell lines MEK/mTORMAP Kinase Kinase KinasesfemaleoncologymTORRNA InterferenceSTAT3 Transcription FactortumormicePyridonesMice NudePyrimidinonesBiologyphosphatidylinositol 3-KinasesSmall InterferingArticle03 medical and health sciencesMediatorSettore MED/04 - PATOLOGIA GENERALECell Line TumormedicinePTENAnimalsPI3K/AKT/mTOR pathwaydrug synergismSettore MED/06 - ONCOLOGIA MEDICAneoplastic stem cellsRPTORCancerJanus Kinase 1medicine.diseaseeverolimusproto-oncogene Proteins c-aktBlockade030104 developmental biologyCancer researchbiology.proteinRNAPTEN phosphohydrolase
researchProduct

Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma

2018

Objective Ampulla of Vater carcinoma (AVC) has a broad spectrum of different prognoses. As such, new moderators of survival are urgently needed. We aimed at clarifying the prognostic role of perineural invasion in AVC. Methods Using PubMed and SCOPUS databases, we conducted the first systematic review and meta-analysis on this topic. Results Analyzing 29 articles for a total of 2379 patients, we found that the presence of perineural invasion increased the risk of all-cause mortality more than 2 times (relative risk [RR], 2.07; 95% confidence interval [CI], 1.78-2.42 [P < 0.0001]; hazard ratio [HR], 2.72; 95% CI, 1.86-3.97 [P < 0.0001]), of cancer-specific mortality more than 6 times (…

Ampulla of Vatermedicine.medical_specialtyEndocrinology Diabetes and MetabolismPNIPerineural invasionPerineumGastroenterology03 medical and health sciencesBroad spectrum0302 clinical medicineEndocrinologypapilla PNI perineural VaterRisk FactorsInternal medicineInternal MedicinemedicineCarcinomaHumansNeoplasm InvasivenessVaterpapillaHepatologybusiness.industryHazard ratioAmpulla of VaterPrognosismedicine.diseaseConfidence intervalPancreatic Neoplasmsmedicine.anatomical_structure030220 oncology & carcinogenesisRelative riskMeta-analysisperineural030211 gastroenterology & hepatologyNeoplasm Recurrence LocalbusinessCarcinoma Pancreatic DuctalPancreas
researchProduct

Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms

2021

High-grade Gastroenteropancreatic Neuroendocrine neoplasms (H-NENs) comprehend well-differentiated tumors (NET G3) and poorly differentiated carcinomas (NEC) with proliferative activity indexes as mitotic count (MC) &gt

Oncologymedicine.medical_specialtyMyeloidmyeloid markersT cellCD3gastroenteropancreatic neuroendocrine neoplasms; myeloid markers; tumor microenvironmentCD33PopulationHuman leukocyte antigenSettore MED/08 - Anatomia PatologicaArticleSurgical pathology03 medical and health sciences0302 clinical medicineInternal medicinemedicinetumor microenvironmenteducation030304 developmental biologymyeloid marker0303 health sciencesTumor microenvironmenteducation.field_of_studybiologybusiness.industryRGeneral Medicinegastroenteropancreatic neuroendocrine neoplasms myeloid markers tumor microenvironmentgastroenteropancreatic neuroendocrine neoplasmsstomatognathic diseasesmedicine.anatomical_structure030220 oncology & carcinogenesisgastroenteropancreatic neuroendocrine neoplasmbiology.proteinMedicinebusiness
researchProduct